Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

NCT02072057 is registered in ClinicalTrials.gov with Kantonsspital Aarau as lead sponsor.

NCT NCT02072057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02072057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.
Lead sponsor
Kantonsspital Aarau
Phase
Phase 2
Overall status
Terminated
Start date
April 20, 2014
Completion date
November 30, 2018
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer cachexia